NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mercy BioAnalytics

Mercy BioAnalytics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://mercybio.com/

Last Round

Series B

Sep 3, 2025

Total Funding Raised

$127.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Mercy BioAnalytics is a biotechnology company that develops a liquid biopsy assay platform for the early detection of cancer through the analysis of tumor-derived extracellular vesicles.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

extracellular vesiclesEVcancer detectionliquid biopsymulti-cancer early detectionMCEDdiagnostic platformbiomarker discoverycompanion diagnosticsoncology researchprecision medicinemachine learning diagnosticsblood-based testingclinical trial supportbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mercy BioAnalytics Comps

Public and private peers based on sector, stage, and business model.

Mercy BioAnalytics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Mercy BioAnalytics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 3, 2025
Series AApr 3, 2023
Series AJan 29, 2021

Key People

Founding team and executive leadership

Dawn Mattoon

Chief Executive Officer

Executive Team

Ellen Snow

Chief Financial Officer

Executive Team

Darrin Crisitello

Chief Commercial Officer

Executive Team

Mercy BioAnalytics Investors

Notable investors and investment history

Mercy BioAnalytics investors
InvestorRounds
Cancer Research HorizonsSeries A
Mindshift CapitalSeries B
iSelect FundSeries A, Series B
Perceptive AdvisorsSeries B
BrightEdgeSeries A
PortfoliaSeries B
Hatteras Venture PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 4, 2026

    Darrin Crisitello appointed as new Chief Commercial Officer.

  • Dec 16, 2025

    Now described as a commercial-stage biotechnology company.

Mercy BioAnalytics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mercy BioAnalytics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mercy BioAnalytics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range62
Year Founded2018
Last FundingSep 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.